In this trial involving double randomization , 140 patients were randomized to receive modified FOLFOX7 plus bevacizumab with IO ( eight-cycle blocks of oxaliplatin treatment ) versus continuous oxaliplatin ( CO ) ; and Ca/Mg versus placebo ( pre - and postoxaliplatin infusion ) .